Proposed changes to the 340B drug pricing program, in addition to other cuts in payments, are being called out by industry associations and providers.

Speeding up the regulatory process has led to uncertainty about the effectiveness of some new drugs.

Hospital utilization is slowing down in its growth, according to a recent survey of hospital administrators. The trend underscores the shift across the healthcare system away from high-cost settings toward lower-cost outpatient utilization.

Venture capital funding continues to pour into healthcare startups, and the pace this year is already expected to top 2017's total figure of $15 billion.

The largest U.S. health insurers aren’t likely to be at risk of negative credit ratings after the Trump administration halted about $10 billion in risk adjustment payments, according to Fitch Ratings.

After work requirements for eligible Medicaid beneficiaries too effect in Arkansas, more than 7,000 people failed to report they worked at least 80 hours in June.

U.S. antitrust enforcers might not move to block CVS Health’s acquisition of health insurance company Aetna, Bloomberg reported.

The FDA has issued a voluntary recall of valsartan, due to concerns of an impurity N-nitrosodimethylamine (NDMA), a known carcinogen, which was found in a batch of the drug manufactured in China. Valsartan is commonly used to control hypertension and heart failure.